NCT05819138

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Not accepted

Summary

This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental.

Conditions

• Diabetes Mellitus, Type 1

Interventions

Type	Name	Description
DRUG	Semaglutide Pen Injector	Semaglutide injection
DRUG	Placebo	Semaglutide placebo injection

Timeline

• Start date: 2023-06-21
• Primary completion: 2027-10-01
• Completion: 2027-12-01
• First posted: 2023-04-19
• Last updated: 2026-03-04

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study